Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides
Journal of Clinical Oncology · 20.10.2024 · 42 (30) · 3550-3560
DOI: 10.1200/jco.23.02641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.10.2024. Verfasst von Erik N Bergstrom und 6 weiteren Autor:innen. Beteiligte Einrichtung: Moores Cancer Center, UC San Diego, La Jolla, CA. Hauptthemen laut MEDLINE: Deep Learning, Breast Neoplasms, Homologous Recombination, Ovarian Neoplasms. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
PURPOSE Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests for detecting HRD require molecular profiling, which is not universally available. METHODS We trained DeepHRD, a deep learning platform for predicting HRD from hematoxylin and eosin (H&E)–stained histopathological slides, using primary breast (n = 1,008) and ovarian (n = 459) cancers from The Cancer Genome Atlas (TCGA). DeepHRD was compared with four standard HRD molecular tests using breast (n = 349) and ovarian (n = 141) cancers from multiple independent data sets, including platinum-treated clinical cohorts with RECIST progression-free survival (PFS), complete response (CR), and overall survival (OS) endpoints. RESULTS DeepHRD predicted HRD from held-out H&E-stained breast cancer slides in TCGA with an AUC of 0.81 (95% CI, 0.77 to 0.85). This performance was confirmed in two independent primary breast cancer cohorts (AUC, 0.76 [95% CI, 0.71 to 0.82]). In an external platinum-treated metastatic breast cancer cohort, samples predicted as HRD had higher complete CR (AUC, 0.76 [95% CI, 0.54 to 0.93]) with 3.7-fold increase in median PFS (14.4 v 3.9 months; P = .0019) and hazard ratio (HR) of 0.45 ( P = .0047). There were no significant differences in nonplatinum treatment outcome by predicted HRD status in three breast cancer cohorts, including CR (AUC, 0.39) and PFS (HR, 0.98, P = .95) in taxane-treated metastatic breast cancer. Through transfer learning to high-grade serous ovarian cancer, DeepHRD-predicted HRD samples had better OS after first-line (HR, 0.46; P = .030) and neoadjuvant (HR, 0.49; P = .015) platinum therapy in two cohorts. CONCLUSION DeepHRD can predict HRD in breast and ovarian cancers directly from routine H&E slides across multiple external cohorts, slide scanners, and tissue fixation variables. When compared with molecular testing, DeepHRD classified 1.8- to 3.1-fold more patients with HRD, which exhibited better OS in high-grade serous ovarian cancer and platinum-specific PFS in metastatic breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Moores Cancer Center, UC San Diego, La Jolla, CA.
- Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA.
- Department of Bioengineering, UC San Diego, La Jolla, CA.
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
- Platform of Transfer in Biological Oncology, Centre Georges-François Leclerc, Dijon, France.
- University of Burgundy-Franche Comté, France.
ORCID-Profile: Erik N Bergstrom, Ammal Abbasi, Marcos Díaz-Gay, Sylvain Ladoire, Scott M Lippman, Ludmil B Alexandrov
Förderung
- NCI NIH HHS
- NIEHS NIH HHS
Zitieren
APA
Bergstrom, E. N., Abbasi, A., Díaz-Gay, M., Galland, L., Ladoire, S., Lippman, S. M., & Alexandrov, L. B. (2024). Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides. Journal of Clinical Oncology, 42(30), 3550-3560. https://doi.org/10.1200/jco.23.02641
Vancouver
Bergstrom EN, Abbasi A, Díaz-Gay M, Galland L, Ladoire S, Lippman SM, et al. Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides. Journal of Clinical Oncology. 2024;42(30):3550-3560. doi:10.1200/jco.23.02641
BibTeX
@article{Bergstrom2024,
author = {Bergstrom, Erik N and Abbasi, Ammal and Díaz-Gay, Marcos and Galland, Loïck and Ladoire, Sylvain and Lippman, Scott M and Alexandrov, Ludmil B},
title = {Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {30},
pages = {3550--3560},
doi = {10.1200/jco.23.02641}
}
EUVIMED